Coherus Scores Review Of An AbbVie Humira Patent
The Patent Trial and Appeal Board has begun a review of an AbbVie Inc. patent covering the megablockbuster autoimmune disease drug Humira, regarding the drug's use to treat rheumatoid arthritis, Coherus...To view the full article, register now.
Already a subscriber? Click here to view full article